IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 3111 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (177 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed1379    
    Printed55    
    Emailed0    
    PDF Downloaded115    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2011  |  Volume : 43  |  Issue : 3  |  Page : 363-364
 

Empirical use of antituberculosis drugs should not be equated to their inappropriate and indiscriminate use


Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), Vasant Kunj, New Delhi, India

Date of Web Publication24-May-2011

Correspondence Address:
Ramesh Kumar
Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), Vasant Kunj, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.81494

Rights and Permissions



How to cite this article:
Kumar R. Empirical use of antituberculosis drugs should not be equated to their inappropriate and indiscriminate use. Indian J Pharmacol 2011;43:363-4

How to cite this URL:
Kumar R. Empirical use of antituberculosis drugs should not be equated to their inappropriate and indiscriminate use. Indian J Pharmacol [serial online] 2011 [cited 2019 Nov 21];43:363-4. Available from: http://www.ijp-online.com/text.asp?2011/43/3/363/81494


Sir,

Tuberculosis is endemic in India accounting for about 20% of the global burden of tuberculosis. About 1.8 million new cases of tuberculosis are reported in India every year. [1] Although effective drugs as well as appropriate guidelines for treatment are available, irrational practices on anti-tuberculosis treatment (ATT) are still widespread in India. [2],[3] Many patients are erroneously diagnosed and treated for tuberculosis. Even quacks (unqualified doctors) with a limited understanding of disease prescribe anti-tubercular drugs in India. The availability of anti-tubercular drugs "over the counter" facilitate their indiscriminate use. The erroneous diagnosis of tuberculosis deprives patients from getting necessary treatment as the actual underlying condition remains undetected. Therefore, it tends to increase the disease burden as well as the cost of healthcare. Moreover, a wide of range of ATT regimens are being used in India by different practitioners [2] and many of them are grossly inadequate, poorly combined, and improperly instituted. Incomplete treatment or incorrect drugs, especially in the initial phase of ATT are a major cause of acquired multi-drug resistance (MDR) tuberculosis, the rising incidence of which India has seen during recent years. According to a latest estimate, India ranks as number one amongst the high burden MDR tuberculosis countries. [1]

Overdiagnosis of tuberculosis is frequently made in patients with prolonged febrile illness, unexplained lymphadenopathy or weight loss, ascites, intestinal obstruction, and pleural effusion etc, without subjecting them to proper diagnostic tests to rule out diseases simulating tuberculosis like other infective illnesses, inflammatory and malignant diseases. Several physicians in India often give over importance to certain diagnostic tests like erythrocyte sedimentation rate, tuberculin skin test, and serological tests, which have a low sensitivity, specificity, and positive predictive value for tuberculosis. As of now, with appropriate clinical evaluation and investigations including microbiological, imaging, and histopathological tests, it is possible to make a correct diagnosis of tuberculosis in majority of infected patients. However, in some cases diagnosing tuberculosis may be a real challenge. This is especially true for extrapulmonary tuberculosis, which is usually paucibacillary and manifestations are often non-specific. A typical example of this is differentiating intestinal tuberculosis from Crohn's disease. In a recent study from India, 43% of 166 patients with definite or probable diagnosis of Crohn's disease had to be given ATT initially because of diagnostic uncertainty even after appropriate evaluation. [4] Since tuberculosis is a treatable condition and is associated with poor outcome if untreated, empirical use of ATT can be justified in cases where index of suspicion is high. However, a close monitoring and follow-up is needed to confirm an appropriate clinical response, to validate its further continuation and to detect drug toxicity at the earliest. In a country with hyperendemicity of tuberculosis, empirical ATT can also be justified in severely ill patients with manifestations consistent with tuberculosis when investigations are non-contributory.

The empirical use of ATT should not be equated to their inappropriate and indiscriminate use. The unwanted prescription of ATT is not safe because of its propensity to cause severe hepatotoxicity and even death by causing acute liver failure (ALF). The reported rates of ATT induced hepatotoxicity vary from 2.3% to 28% and are higher among the Indian population (11.5%) than the Western population (4.3%). [5] The presence of malnutrition, co-infection with hepatotrophic viruses, HIV infection, and alcoholism in India leave such patients at a higher risk of ATT hepatototoxicity. The mortality rates from ATT-induced hepatitis after development of jaundice vary from 4% to 12%. A recent large study from India has identified 63% of patients who developed ATT-induced ALF received ATT with presumptive diagnosis of tuberculosis and the mortality rates among them was very high (67%). [3] Thus, ATT, not only can save lives, but its inappropriate use can also take lives.

The intermittent ATT (thrice weekly) has been found to be equally effective and safer in terms of adverse events in comparison to daily treatment. Even though India has adopted directly observed treatment short course (DOTS), which delivers intermittent treatment, under the Revised National Tuberculosis Control Programme (RNTCP) decades ago, its success has largely been suboptimal to date. In a country where as high as 65% of households seek healthcare from private sector, only 0.3% of private practitioners are implementing RNTCP. [6] The situation deserves a serious note and warrants awareness programs in order to prevent irrational practices on tuberculosis in India. Since private practitioners treat a substantial proportion of these patients, there should be strategies to provide DOTS training to them in order to improve their knowledge, attitude and practice on tuberculosis. All health providers should be encouraged to adopt RNTCP, which is the best way to practice tuberculosis as per international standard. The success, feasibility, and cost-effectiveness of integrated public private collaboration have already been proved. [7],[8] Like in several developed countries, there should be a drug and therapeutics committee to look after proper use of medicines at all levels of healthcare. The quacks should be prohibited from using anti-tubercular drugs. Moreover, appropriate laboratory support and frequent referral to higher centers, in case of diagnostic uncertainty, can avoid over or under diagnosis of tuberculosis.

 
  References Top

1.Global Tuberculosis Control 2009 Surveillance Planning Financing. Geneva: Word Health Organization; 2009 (WHO/ HTM/TB/2009.411).  Back to cited text no. 1
    
2.Uplekar M, Juvekar S, Morankar S, Rangan S, Nunn P. Tuberculosis patients and practitioners in private clinics in India. Int J Tuberc Lung Dis 1998;2:324-9.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.Kumar R, Shalimar, Bhatia V, Khanal S, Sreenivas V, Gupta SD, et al. Antituberculosis therapy-induced acute liver failure: Magnitude, profile, prognosis, and predictors of outcome. Hepatology 2010;51:1665-74.  Back to cited text no. 3
    
4.Das K, Ghoshal UC, Dhali GK, Benjamin J, Ahuja V, Makharia GK. Crohn′s disease in India: A multicenter study from a country where tuberculosis is endemic. Dig Dis Sci 2009;54:1099-107.   Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: A meta-analysis. Chest 1991;99:465-71.  Back to cited text no. 5
    
6.TB India 2009: RNTCP Status report. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi - 110001. Available from: http://www.tbcindia.org. [last accessed on 2010 Oct 15].  Back to cited text no. 6
    
7.Dewan PK, Lal SS, Lonnroth K, Wares F, Uplekar M, Sahu S, et al. Improving tuberculosis control through public-private collaboration in India: Literature review. BMJ 2006;332:574-8.   Back to cited text no. 7
[PUBMED]  [FULLTEXT]  
8.Floyd K, Arora VK, Murthy KJ, Lonnroth K, Singla N, Akbar Y, et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ 2006;84:437-45.  Back to cited text no. 8
[PUBMED]  [FULLTEXT]  




 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow